Biomea stock crashed Friday after the Food and Drug Administration placed two of the company’s diabetes treatment studies on hold, citing concerns of liver toxicity.
YouTube channel.” vid-name=”This Is The Biggest Investing Mistake – And I’ve Made It. How To Sell Stocks Before Losses Pile Up” vid-cat=”Investing Education” vid-date=”02/25/2022″ vid-date-tmsp=”1645752374″ vid-image=”https://www.investors.com/wp-content/uploads/2022/02/Ali-Investing-Mistake-640×360.jpeg” vid-authors=”ALISSA CORAM”>
X
The drug, BMF-291, was in early-stage testing for patients with type 1 and type 2 diabetes. The FDA noted there were possible drug-related liver toxicities after Biomea Fusion (BMEA) increased the dosage in patients with type 2 diabetes.
“We respect the FDA’s decision and agree that patient safety is paramount and our top priority,” Chief Executive Thomas Butler said in a statement.
The company noted BMF-219 has generally been well tolerated in testing thus far.
But in early trading on today’s stock market, Biomea stock plummeted 66.7% to 3.74. Shares hit their lowest point in two years at the open.
Biomea Stock: Most Advanced Program
The study in type 2 diabetes treatment is Biomea’s most advanced. The company is also working on treatments for forms of leukemia, lymphoma and myeloma, as well as drugs for solid tumors.
Biomea stock went public in 2021. Shares tumbled through half of 2022, but took off in the latter part of the year and eventually topped out at 43.69 in mid-2023. Since then, Biomea shares have slumped considerably.
Today, Biomea stock has a low Relative Strength Rating of 7, putting its 12-month performance in the lowest 7% of all stocks, according to IBD Digital.
Follow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.
YOU MAY ALSO LIKE:
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Novavax, With A 369% Gain, Reverses Bullish Gains After Key FDA Move
IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks
Looking For The Next Apple Or Amazon? Start With These S&P 500-Beating Lists
Signup bonus from
